202 related articles for article (PubMed ID: 6227068)
1. The quest for an intrinsic C3 activating factor in human glomerular disease.
Roberts JL; Lewis EJ
Surv Immunol Res; 1982; 1(2):191-8. PubMed ID: 6227068
[No Abstract] [Full Text] [Related]
2. [Progress in the knowledge of complement. II. Nephritic factors].
Leibowitch J; Lesavre P
Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
[No Abstract] [Full Text] [Related]
3. Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.
Tanuma Y; Ohi H; Hatano M
Immunology; 1989 Dec; 68(4):445-8. PubMed ID: 2532618
[TBL] [Abstract][Full Text] [Related]
4. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
Seya T; Holers VM; Atkinson JP
J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
[TBL] [Abstract][Full Text] [Related]
5. Nonimmunoglobulin C3 activating factor in membranoproliferative glomerulonephritis.
Bartlow BG; Roberts JL; Lewis EJ
Kidney Int; 1979 Mar; 15(3):294-302. PubMed ID: 390213
[No Abstract] [Full Text] [Related]
6. Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.
Daha MR; Van Es LA
Immunology; 1981 May; 43(1):33-8. PubMed ID: 6166544
[TBL] [Abstract][Full Text] [Related]
7. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of action and clinical importance of C3-nephritic-factor (author's transl)].
Lanzer G; Pogglitsch H; Tilz GP
Acta Med Austriaca; 1981; 8(1):7-13. PubMed ID: 6908995
[TBL] [Abstract][Full Text] [Related]
9. [Structure and function of alternative pathway components of complement].
Tomita M; Sugita Y
Tanpakushitsu Kakusan Koso; 1986 Jul; 31(9 Suppl):847-64. PubMed ID: 3641329
[No Abstract] [Full Text] [Related]
10. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes.
Rother U
J Immunol Methods; 1982; 51(1):101-7. PubMed ID: 6921216
[TBL] [Abstract][Full Text] [Related]
11. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
12. [Progress in the knowledge of complement. I. Structure, activation and control of the complement system].
Lesavre P; Leibowitch J
Nouv Presse Med; 1979 Jun; 8(29):2385-7. PubMed ID: 493022
[No Abstract] [Full Text] [Related]
13. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
Sobel AT; Cooper NR; Schreiber RD
J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
15. Molecular biology and chemistry of the alternative pathway of complement.
Müller-Eberhard HJ; Schreiber RD
Adv Immunol; 1980; 29():1-53. PubMed ID: 6158260
[No Abstract] [Full Text] [Related]
16. Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection.
Fearon DT; Austen KF
N Engl J Med; 1980 Jul; 303(5):259-63. PubMed ID: 6900901
[No Abstract] [Full Text] [Related]
17. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
18. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
19. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
[TBL] [Abstract][Full Text] [Related]
20. Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis.
Wyatt RJ; McAdams AJ; Forristal J; Snyder J; West CD
Kidney Int; 1979 Oct; 16(4):505-12. PubMed ID: 398417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
